Publications

5813 Results

Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801)

Authors
M Othus;E Sharon;M Wu;V Sondak;A Ribas;S Patel
Journal / Conference
Sage Journals 2025 Oct;22(5):571-577. doi: 10.1177/17407745251321371. Epub 2025 Mar 18. PMID: 40099861; PMCID: PMC12353050.
Year
2025
Research Committee(s)
Melanoma
PMID
40099861
PMC
PMC12353050
Study Number(s)
S1801

Development and validation of a novel conditional event-free survival tool in diffuse large B-cell lymphoma

Authors
Z Chen;D Luan;R Rask;L Jakobsen;M Maurer;T El-Galaly;L Nastoupil;J Cerhan;C Flowers;B Link;I Lossos;D Stephens;J Cohen;J Habermann;G Nowakowski;N Bartlett;J Friedberg;B Kahl;J Leonard;P Brown;K Smedby;M Jerkeman;P Martin
Journal / Conference
Journal of Clinical Oncology
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1001

Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;N Vogelzang;I Thompson;N Agarwal
Journal / Conference
European Urology Feb;85(2):171-176
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37085425
PMC
PMC10662935
Study Number(s)
S1216

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Authors
G Garcia-Manero;N Podoltsev;M Othus;J Pagel;J Radich;M Fang;D Rizzieri;G Marcucci;SA Strickland;MR Litzow;M Savoie;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;JE Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;F Appelbaum;HP Erba
Journal / Conference
Leukemia Jan;38(1):58-66
Year
2024
Research Committee(s)
Leukemia
PMID
PMID37935977
Study Number(s)
S1203

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Authors
S Lerner;D McConkey;C Tangen;JJ Meeks;T Flaig;X Hua;S Daneshmand;A Alva;MS Lucia;D Theodorescu;A Goldkorn;M Milowsky;W Choi;R Bangs;D Gustafson;M Plets;IM Thompson
Journal / Conference
Clinical Cancer Research Jan 17;30(2):444-449
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37966367
PMC
PMC10824507
Study Number(s)
S1314

A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

Authors
S Patel;M Othus;Y Chae;M Dennis;S Gordon;D Mutch;W Samlowski;W Robinson;E Sharon;C Ryan;G Lopez;M Plets;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Jan 5;30(1):33-38
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID37882676
PMC
PMC10842092
Study Number(s)
S1609

Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

Authors
B Faltas;Z Bai;M Osman;M Brendel;C Tangen;T Flaig;M Plets;MS Lucia;D Theodorescu;D Gustafson;S Daneshmand;J Meeks;W Choi;C Dinney;O Elemento;S Lerner;D McConkey;F Wang
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1314

PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)

Authors
B Maughan;M Plets;Y Ged;C Tangen;U Vaishampayan;S Lerner;S Lerner;I Thompson
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S2200

SWOG S2210: A PHASE II STUDY OF NEOADJUVANT CARBOPLATIN FOR LOCALIZED, HIGH RISK PROSTATE CANCER WITH GERMLINE BRCA1/2 MUTATIONS

Authors
H Cheng;S Callis;D Lin;E Yu;T Dorff;A Kase;C Tangen;D Petrylak;S Lerner
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S2210

AMBASSADOR Alliance A031501: Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma (MIBC) vs Observation

Authors
A Apolo;K Ballman;G Sonpavde;S Berg;W Kim;R Parikh;M Teo;R Sweis;D Geynisman;P Grivas;E Levine;Z Reichert;J Kim;M Bilen;Y Wen;O Hahn;S Halabi;G Perez;M Morris;J Rosenberg
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral; J Clin Oncol 42, 2024 (suppl 4; abstr LBA531)
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/A031501